FindTrial
Sign In

Placebo preparation identical to verum except that it does not include the active substance

DRUG2 trials

Sponsors

ROXALL Medizin GmbH

Conditions

2008)2008) guidelineBousquet et al.Patients with moderate-to-severe allergic rhinitis / rhinoconjunctivitis due to grass pollen for at least two years according to the Allergic Rhinitis and its Impact on Asthma (ARIA) guideline (Bousquet et al.Patients with moderate-to-severe allergic rhinitis / rhinoconjunctivitis due to house dust mites (HDM) for at least one year according to the Allergic Rhinitis and its Impact on Asthma (ARIA

Phase 2

Phase II-III study to assess the efficacy and safety of sublingual immunotherapy in patients suffering from grass pollen allergy
Active, not recruitingCTIS2024-517524-18-00
ROXALL Medizin GmbH2008), Patients with moderate-to-severe allergic rhinitis / rhinoconjunctivitis due to grass pollen for at least two years according to the Allergic Rhinitis and its Impact on Asthma (ARIA) guideline (Bousquet et al.
Start: 2025-10-22Target: 30Updated: 2025-09-05
Phase II-III study to assess the efficacy and safety of sublingual immunotherapy in patients suffering from house dust mite allergy. A prospective, international, randomized, double-blind, placebo-controlled, multicentre, phase II-III trial.
Not yet recruitingCTIS2025-523119-12-00
ROXALL Medizin GmbH2008) guideline, Bousquet et al., Patients with moderate-to-severe allergic rhinitis / rhinoconjunctivitis due to house dust mites (HDM) for at least one year according to the Allergic Rhinitis and its Impact on Asthma (ARIA
Target: 40Updated: 2026-01-19